WHO ICTRP trial
The effectiveness of Rivastigmine on treatment of Tardive dyskinesia
IRCT2012092910964N1 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT2012092910964N1 |
|---|---|
| Public title | The effectiveness of Rivastigmine on treatment of Tardive dyskinesia |
| Scientific title | The effectiveness of Rivastigmine on reducing the symptoms of Tardive dyskinesia in patients with Schizophrenia |
| Primary sponsor | University of Social Welfare and Rehabilitation Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 2-3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Tardive dyskinesia. Drug-induced dystonia;Drug-induced dystonia |
| Interventions | Intervention 1: in intervention group: Rivastigmine,1.5 mg capsules, twice a day, in 4 weeks. Intervention 2: in control group: sugar,1.5 mg capsules, twice a day, in 4 weeks.;Treatment - Drugs;Treatment - Drugs;in intervention group… |
| Registration date | Jan 8, 2013 |
| Target size | 40 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: